Goldman Sachs Keeps Their Sell Rating on Novartis AG (NOVN)
In a report released today, James Quigley from Goldman Sachs maintained a Sell rating on Novartis AG, with a price target of CHF105.00.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Quigley covers the Healthcare sector, focusing on stocks such as Novartis AG, Sartorius, and Merck KGaA. According to TipRanks, Quigley has an average return of -10.4% and a 33.75% success rate on recommended stocks.
In addition to Goldman Sachs, Novartis AG also received a Sell from HSBC’s Rajesh Kumar in a report issued on March 17. However, yesterday, Bank of America Securities reiterated a Buy rating on Novartis AG (Six Swiss: NOVN).
Based on Novartis AG’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of CHF13.44 billion and a net profit of CHF2.43 billion. In comparison, last year the company earned a revenue of CHF13.56 billion and had a net profit of CHF2.82 billion
Read More on CH:NOVN:
Disclaimer & DisclosureReport an Issue
- Largest borrow rate increases among liquid names
- Buy Rating on Novartis: Durable Growth from New Therapies and Late‑Stage Pipeline Offsets Near‑Term Margin Pressure and LOE Risk
- Novartis announces two-year results from Phase III APPLAUSE-IgAN study
- Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy
- Novartis: Excellergy Deal Adds Long‑Dated Pipeline Risk Amid LOE Headwinds, Supporting Sell Rating
